Fast Five Quiz: Type 2 Diabetes Management

Anne L. Peters, MD


April 27, 2022

The American College of Cardiology and ADA recommend SGLT2 inhibitors in patients with type 2 diabetes and established ASCVD, regardless of the patient's hemoglobin A1c. SGLT2 inhibitors have been demonstrated to significantly reduce the risk for major adverse cardiovascular events, cardiovascular mortality, heart failure, and CKD. In the EMPEROR-Reduced Clinical trial, empagliflozin was shown to reduce the risk for cardiovascular death and decline in GFR. This was later shown to be a class effect through the 2017 CANVAS trial; individuals who received canagliflozin experienced a 30% reduction in the risk for heart failure hospitalizations, cardiovascular death, and end-stage kidney disease.

Although GLP-1 RA has shown greater efficacy at glucose lowering compared with SGLT2 inhibitors, it is currently recommended for patients without albuminuria, heart failure, or CVD.

Learn more about type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.